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Abstract
Background: Mycobacterium tuberculosis is a common, devastating cause of meningitis in HIV-infected persons. Due to
international rollout programs, access to antiretroviral therapy (ART) is increasing globally. Starting patients with HIV-
associated tuberculous meningitis (TBM) on ART during tuberculosis (TB) treatment may increase survival in these patients.
We undertook this study to describe causes of meningitis at a secondary-level hospital in a high HIV/TB co-infection setting
and to determine predictors of mortality in patients with TBM.
Methods: A retrospective review of cerebrospinal fluid findings and clinical records over a six-month period (March 2009–
August 2009). Definite, probable and possible TBM were diagnosed according to published case definitions.
Results: TBM was diagnosed in 120/211 patients (57%) with meningitis. In 106 HIV-infected patients with TBM, six-month
all-cause mortality was lower in those who received antiretroviral therapy (ART) during TB treatment; hazard ratio = 0.30
(95% CI = 0.08–0.82). Factors associated with inpatient mortality in HIV-infected patients were 1) low CD4+ count at
presentation; adjusted odds ratio (AOR) = 1.4 (95% confidence interval [CI] = 1.03–1.96) per 50 cells/mL drop in CD4+
count and, 2) higher British Medical Research Council TBM disease grade (2 or 3 versus 1); AOR = 4.8 (95% CI = 1.45–
15.87).
Interpretation: Starting ART prior to or during TB treatment may be associated with lower mortality in patients with HIV-
associated TBM. Advanced HIV and worse stage of TBM disease predict in-hospital mortality in patients presenting with
TBM.
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Introduction
Meningitis causes significant mortality and morbidity in HIV-
infected persons [1–4]. Tuberculous meningitis (TBM) accounts
for a substantial proportion of cases, particularly in high
tuberculosis (TB) prevalence areas [3]. Globally, access to
antiretroviral therapy (ART) is rapidly increasing due to ART
rollout programs [5]. Starting ART during TB treatment is
associated with reduced mortality in HIV/TB co-infected patients
[6,7]. However, few studies have reported the influence of ART on
the outcome of patients with HIV-associated TBM [8–10]. In this
study, we report the causes of meningitis at a secondary-level
hospital in a high HIV/TB prevalence setting in the era of
increasing availability of ART. We also describe the presentation
and outcome of patients with TBM and investigate the predictors
of mortality (including ART) in these patients.
Methods
Ethics statement
The ethics committee of the University of Cape Town (UCT)
approved the study (REC REF 223/2010). As this was a
retrospective folder review, and data were analysed anonymously
outside of the clinical setting, the ethics committee of UCT waived
the requirement for informed consent and informed consent was
not obtained.
Setting and population
We conducted a retrospective study at GF Jooste Hospital, a
200-bed public sector referral hospital that serves adult patients
from a community of approximately 1.3 million people. This
predominantly low-income, high-density population is at the
epicenter of the TB/HIV pandemic; in some parts of the referral
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area the reported TB case notification rate exceeds 1500 cases per
100 000 people per year and the HIV seroprevalence at antenatal
clinics reaches 30% [11]. All patients accessing public sector care
with suspected meningitis are referred to GF Jooste Hospital for
investigations, including a lumbar puncture (LP). Adult patients
($18 years) who had a LP performed over a six-month period (1
March 2009–31 August 2009) were identified from laboratory logs
and included in the study.
Procedure
As per standard protocol at the hospital laboratory [3],
cerebrospinal fluid (CSF) samples underwent macroscopic exam-
ination, protein and glucose quantification, cell count, Gram stain,
and bacterial and fungal culture. India ink staining and/or
Crytococcus Latex Antigen Testing (CLAT) were also performed.
If the clinical presentation or initial CSF findings were suggestive
of TBM (as determined by the attending clinician), Ziehl-Neelsen
(ZN) staining of sediment and/or Mycobacterium tuberculosis (M.
tuberculosis) culture was performed. If acid-fast bacilli (AFB) were
cultured from CSF, TB polymerase chain reaction (PCR)
[Genotype MTBDRplus, Hain Lifesciences]) tests were performed
to further identify mycobacteria species, and to determine first-line
drug susceptibility (to rifampicin and isoniazid). In cases where
rifampicin-resistant organisms were identified, additional drug
susceptibility testing was performed by conventional methods.
Syphilis serology (venereal disease research laboratory and/or
Treponema pallidum hemagglutination assay), cytology and viral
PCR examination were performed at attending clinician’s
discretion.
All CSF findings were reviewed. Microbiological diagnoses (i.e.
where CSF analysis identified a specific etiological cause) were
documented. Clinical records of patients with ‘markedly abnor-
mal’ CSF who did not have a microbiological diagnosis were
reviewed. In line with a previous study [3], CSF was considered to
be ‘markedly abnormal’ when one or more of the following were
present: 1) neutrophils .5 cells6106/L, 2) lymphocytes.20
cells6106/L, 3) protein .1 g/L, and 4) glucose ,2.2 mmol/L.
Patients who did not present with symptoms and/or signs of
meningitis such as headache, photophobia, seizure, vomiting,
altered mental state, neck stiffness or focal neurological deficit (e.g.
patients with peripheral neuropathy) and those in whom an
alternative diagnosis was made (e.g. subarachnoid hemorrhage),
were excluded from the analysis. Data recorded for patients with
TBM included medical and treatment history prior to admission,
history of the presenting complaint (s), clinical examination, results
of investigations, inpatient management and admission outcome.
Additional information such as date of starting ART, was obtained
from primary care clinic records. We used hospital medical notes,
the National Health Laboratories Service database and the
electronic hospital and primary care clinic (TB and ART)
attendance registers to trace patients, in order to determine
outcome (alive, dead or lost to follow-up) six months after LP was
performed.
Patients received standardized TB treatment according to
national treatment guidelines using Directly Observed Therapy
Short-course (DOTS) either at the primary care TB clinic, or
delivered to home by lay health care workers [12]. The duration of
TB treatment (at least six to nine months) depended on the
attending clinician’s discretion. Patients with a new diagnosis of
tuberculosis received isoniazid, rifampin, pyrazinamide, and
ethambutol for two months (dosing schedules detailed in Table
S1). This was followed by rifampicin and isoniazid for at least four
months. The retreatment regimen included rifampicin, isoniazid,
pyrazinamide, ethambutol and intramuscular streptomycin during
the initial two months of treatment, followed by rifampicin,
isoniazid, pyrazinamide and ethambutol for one month, followed
by rifampicin, isoniazid and ethambutol for at least five months
(dosing schedules detailed in Table S2). At the time of the study,
national guidelines advised ART for all patients with a CD4+
count of less than 200 cells/mL or World Health Organization
(WHO) stage 4 disease [13]. First-line ART during this study was
stavudine, lamivudine, and either nevirapine or efavirenz.
Efavirenz was preferred for patients who were receiving
rifampicin-based antituberculosis treatment.
Definitions
Definite TBM was diagnosed when 1) AFB were seen in CSF,
2) AFB or M. tuberculosis was cultured from CSF or 3) M. tuberculosis
was detected by PCR from CSF. Probable and possible TBM were
diagnosed according to modified published case definitions
[10,14]. Probable TBM was diagnosed when: 1) a patient
presented with clinical features of meningitis and 2) suggestive
CSF findings of TBM (total white cell count .5 cells6106/L,
protein .0.45 g/L and glucose ,2.2 mmol/L), plus 3) one or
more of the following i) chest radiograph findings consistent with
pulmonary TB, ii) an extra-meningeal specimen positive for AFB,
iii) other evidence of extra-meningeal TB (e.g. abdominal
ultrasound features) or iv) brain computed tomography (CT)
evidence of TBM including one or more of the following: basal
meningeal enhancement, hydrocephalus or infarctions. Possible
TBM was diagnosed when: 1) a patient presented with clinical
features of meningitis and either 2) four or more of the following
were present i) a history of TB ii) a predominance of CSF
lymphocytes (.50%), iii) illness duration of more than five days iv)
CSF glucose ,2.2 mmol/L, v) altered consciousness, vi) clear or
yellow CSF with protein.1 g/L, vii) focal neurological signs, or 3)
‘markedly abnormal’ CSF (excluding isolated hypoglycemia) with
evidence of TB elsewhere.
Patients were excluded from the probable and possible TBM
groups if an alternative cause of meningitis was found, or if they
improved with no treatment or alternative treatment in the
absence of TB treatment. Cryptococcal meningitis (CM) was
diagnosed when CSF India ink stain, CLAT or Cryptococcus
neoformans culture was positive. Bacterial meningitis was
diagnosed when: 1) bacteria were isolated from CSF or 2) a
patient presented with clinical features of meningitis and i) a CSF
polymorphonuclear cell predominance and showed a good
response to antibacterial treatment in the absence of TB
treatment, or ii) a CSF polymorphonuclear cell count .1000
cells6106/L, regardless of outcome. Viral meningitis was
diagnosed when a patient presented with clinical meningitis and:
1) a virus was identified from CSF, or 2) a CSF lymphocytic
predominance and had symptom resolution in the absence of
antimicrobial treatment. Loss to follow-up was defined as being
unable to trace a patient six months after LP, using the methods
described above.
Statistical analysis
Univariate analysis was performed to 1) identify significant
differences between patients who did, and did not die during
hospitalization and at six months follow-up and 2) identify
significant differences between patients with definite and those
with probable/possible TBM. Continuous variables were com-
pared using the Student t-test or Mann-Whitney U test, and
categorical variables were compared by Fisher’s exact test.
Variables associated with inpatient mortality (p,0.2) were
evaluated using multivariate analysis. Stepwise logistic regression
was used to identify variables predictive of inpatient mortality in all
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TBM patients (regardless of HIV status) and subsequently, in
HIV-infected patients only. A Cox proportional hazard model was
used to assess the association of ART started before or during TB
treatment with six-month mortality in HIV-infected patients who
survived hospitalization. The validity of the model’s assumptions
was tested with Schoenfeld residuals.
A p-value,0.05 was considered statistically significant. Time to
death was summarized by use of Kaplan-Meier estimates. The
statistical analyses were performed with GraphPad Prism version 5
and STATA version 10.1 software.
Results
Causes of ‘markedly abnormal’ CSF
During the study period, 812 LPs were performed in 698
patients. CSF analysis was ‘markedly abnormal’ (n = 146), and/or
identified a cause of meningitis (n = 107) in 253 patients. Figure 1
shows the reasons for exclusion (n = 42) and diagnoses in 211
patients who were diagnosed with meningitis. The most frequent
microbiological diagnoses were CM, and TBM, which accounted
for 45% (48/107), and 44% (47/107), of cases respectively. Fifty-
seven percent (120/211) of patients with meningitis were
diagnosed with definite (n = 47), probable (n = 35) or possible
(n = 38) TBM.
Findings in patients with TBM
The demographic, clinical and investigative findings for patients
with definite, probable and possible TBM are detailed in Tables 1
and 2. Eighty-eight percent of patients with TBM were HIV-
infected with a median CD4+ count of 79 cells/uL (interquartile
range [IQR] = 39–137); 20 (19%) of these patients were receiving
ART at the time of presentation. The majority of TBM cases
(68%) presented with advanced TBM disease (British Medical
Research Council [BMRC] disease grade 2 or 3) [15] 7 days
(median, IQR = 3–15 days) after symptom onset. 26/115 (23%) of
patients for whom this information was available were receiving
TB treatment at time of presentation for a median duration of 106
days (IQR = 50–178). Disseminated TB was common; 87/114
Figure 1. Flow diagram of differential diagnoses in patients with ‘markedly abnormal’ CSF and/or microbiological-confirmed
meningitis. 1 Common alternative diagnoses include: hypoglycemia (n = 9), intracranial bleed (n = 7) and peripheral nerve disorders (n = 6).
2 Including 5 patients with CSF culture-confirmed bacterial meningitis. Organisms isolated include: Streptococcus pneumonia (n = 3), beta-hemolytic
Streptococcus (n = 1), Neisseria meningitides (n = 1). 3 Including 1 patient with positive CSF polymerase chain reaction for both cytomegalovirus and
herpes simplex-1 virus. 4 Other causes of meningitis include: Acute HIV infection (n = 1), Toxoplasma gondii meningoencephalitis (n = 1), disseminated
Burkitt’s lymphoma (n= 1), disseminated large B-cell lymphoma (n= 1), chronic resolving TBM immune reconstitution inflammatory syndrome (n = 1).
5 Including patients with the following differential diagnoses: 1) TBM with tuberculoma or toxoplasmosis (n = 1); 2) partially treated bacterial
meningitis, viral meningitis or TBM (n= 3); and 3) viral meningitis or TBM (n = 3). CSF, cerebrospinal fluid.
doi:10.1371/journal.pone.0020077.g001
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(76%) of patients presented with features of extra-meningeal TB.
Chest radiograph abnormalities consistent with TB were observed
in 74% (76/103) of patients. Abdominal ultrasound was performed
in 27 patients, of which 25 (93%) showed features of TB. In
addition, AFB were seen on microscopy, or M. tuberculosis was
cultured, from one or more extra-meningeal specimens from 26
patients; specimens included sputum (n = 21), lymph node fine
needle aspiration biopsy (n = 6), pleural fluid (n = 1), blood (n = 5)
and urine (n = 3).
Atypical CSF findings in patients with definite TBM (n = 47)
included a polymorphonuclear cell predominance (.50% of total
leucocyte count) in six (13%), a glucose level of more than
2.2 mmol/L in 13 (28%), a protein concentration of less or equal
to 0.45 g/L in three (6%) and a total leucocyte count of five or less
cells6106/L in two (4%). No patient with definite TBM had
completely normal CSF (both biochemistry and cell count). ZN
staining was requested for CSF specimens from 88 patients,
including 47 (100%) definite TBM, 24 (69%) probable TBM and
25 (66%) possible TBM cases. 76/88 of these specimens (86%)
were insufficient for TB microscopy. Of the 12 TBM cases who
had CSF direct smear examination performed, AFB were
visualized in one. Cerebrospinal fluid M. tuberculosis culture was
requested for 106 patients including 47 [100%] definite TBM, 31
[89%] probable TBM, and 28 [74%] possible TBM cases.
Significantly less patients with probable and possible TBM had
M. tuberculosis culture performed, compared to those with definite
TBM, who by definition required a positive culture (p = 0.02, and
p = 0.0009, respectively). Drug susceptibility testing for first-line
TB drugs (rifampicin and isoniazid) was performed on 40/47
(85%) of isolates; 35 were susceptible to rifampicin and isoniazid,
three were resistant to isoniazid, one was resistant to rifampicin,
and one was resistant to both rifampicin and isoniazid (multidrug-
Table 1. Demographic and clinical characteristics of patients with definite, probable and possible tuberculous meningitis (TBM).
Definite TBM (n=47) Probable TBM (n=35) Possible TBM (n=38)
Age, median (IQR) 35 (28–42) 36 (29–51) 38 (28–42)
Female, n/N (%) 22/47 (47) 16/35 (46) 22/38 (58)
HIV status, n/N (%)
Infected 43/47 (91) 27/35 (77) 36/38 (95)
Uninfected 2/47 (4) 5/35 (14) 1/38 (3)
Unknown 2/47 (4) 3/35 (9) 1/38 (3)
CD4+ cell count, median (IQR)1 63 (35–115) 79 (36–150) 109 (33–201)
On ART at presentation, n/N (%)2 9/41 (22) 6/27 (22) 5/35 (14)
Previous TB, n/N (%) 15/43 (35) 7/34 (21) 12/38 (32)
On TB treatment at time of LP, n/N (%) 9/43 (21) 8/34 (24) 9/38 (24)
Symptom onset to LP, median (IQR) 7 (4–15) 6 (3–21) 3 (2–11)
Neurological symptoms, n/N (%)
Headache 26/42 (62) 18/34 (53) 17/38 (45)
Confusion3 23/42 (55) 21/34 (62) 17/38 (45)
Neck pain/stiffness3 12/42 (29) 8/34 (24) 5/38 (13)
Nausea/vomiting 15/42 (36) 11/34 (32) 12/38 (32)
Photophobia/blurred vision/diplopia 11/42 (26) 8/34 (24) 6/38 (16)
Seizures 7/42 (17) 2/34 (6) 6/38 (16)
Neurological signs, n/N (%)
BMRC TBM Disease Grade4
1 10/42 (24) 7/34 (21) 16/38 (42)
2 29/42 (69) 23/34 (68) 20/38 (53)
3 3/42 (7) 4/34 (12) 2/38 (5)
Confusion5 29/42 (69) 22/34 (65) 23/38 (61)
Neck stiffness5 31/42 (74) 23/34 (68) 19/38 (50)*
Focal neurological signs 9/42 (21) 17/34 (50)* 2/38 (5)**
IQR, interquartile range; n, number of patients; N, total number of patients for whom results were available; HIV, human immunodeficiency virus; ART, antiretroviral
therapy; TB, tuberculosis; LP, lumbar puncture; D4T, stavudine 30 mg twice daily; 3TC, lamivudine 150 mg twice daily or 300 mg daily; EFV, efavirenz 600 mg nightly;
AZT, zidovudine 300 mg twice daily; NEV, nevirapine 200 mg twice daily; ddI, didanosine 400 mg daily; LPV/rtv, lopinavir/ritonavir 800/200 mg twice daily.
*Significantly different (p,0.05) from patients with definite TBM;
**p,0.01.
1Only performed in HIV-infected patients.
2N includes HIV-infected patients only. Treatment regimens included: 1) D4T, 3TC, EFV (n = 11), 2) AZT, 3TC, NEV (n = 3), 3) D4T, 3TC, NEV (n = 3), 4) AZT, 3TC, EFV (n = 1),
5) AZT, 3TC, LPV/rtv (n = 1), 6) AZT, ddI, LPV/rtv (n = 1).
3Refers to symptoms reported by patient or family only.
4British Medical Research Council TBM disease grades: 1- Glasgow coma scale (GCS) 15 with no neurological deficit; 2- GCS 11–14 without neurological deficit, or GCS 15
with focal neurological deficit; 3- GCS#10.15
5Refers to clinical findings on physical examination only.
doi:10.1371/journal.pone.0020077.t001
Tuberculous Meningitis in a HIV Prevalent Setting
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20077
resistant [MDR] organisms). The latter two patients both died
during hospitalization after starting regimen 2 TB treatment (prior
to the availability of M. tuberculosis drug susceptibility testing
results). In two additional patients MDR M. tuberculosis strains were
cultured from extra-meningeal specimens prior to admission. One
of these patients presented on a MDR TB drug regimen (i.e.
ethambutol, pyrazinamide, ethionamide, ofloxacin and kanamy-
cin) and was alive at 6-months follow-up. The M. tuberculosis drug
resistance profile was unknown for the other patient at TBM
presentation; the patient died during hospitalization after starting
regimen 2 TB treatment.
Table 3 describes the management and outcome in patients
with TBM. Five of 89 patients not receiving TB treatment at the
time of presentation, failed to initiate TB treatment after LP; all
five subsequently died. In one patient with definite TBM who did
not commence TB treatment, the diagnosis was not considered
initially as routine CSF investigations was mildly abnormal (only
abnormality: lymphocyte count = 66106/L) and there were no
features of extra-pulmonary TB on chest radiograph. The
remaining four patients (2-probable TBM, 2-possible TBM) died
shortly after admission (within 24 hours), prior to TB drug
initiation. The exact time of TB treatment initiation at
presentation was known for 82/84 remaining patients: 11 patients
started TB treatment 1–4 days prior to LP, but after symptom
onset; 63 patients started TB treatment within 24 hours of LP; and
8 patients started TB treatment more than 24 hours after LP at a
median time of three days (range, 2–8 days). Adjunctive
corticosteroid treatment was started in 64/113 (57%) of patients
during admission; significantly more patients with definite TBM
received corticosteroids compared to those with possible TBM
(71% versus 32%, p = 0.0007). The proportion of patients with
probable TBM who received corticosteroids (70%) was similar to
that of the definite TBM group. No patient received any other
adjunctive therapy e.g. acetazolamide, or surgery. Overall
inpatient mortality during hospitalization was 38% (45/120
patients), four days (median, IQR: 3–9 days) after LP (Figure 2).
Among those discharged from hospital, 57% (31/54 patients) of
HIV-infected patients (not on ART at time of presentation)
initiated ART during six months of TB treatment. ART regimens
for these patients are detailed in tables 1 and 3. At six-month
follow-up, 48% of all TBM patients had died and 10% were lost to
follow-up. Baseline characteristics did not differ significantly
between patients who were retained in care and those who were
lost to follow-up (data not shown). However, there was a trend to
higher CD4+ counts in HIV-infected patients lost to follow-up
compared to those who were not (median [IQR], 164 [71–250]
cells/mL compared to 68 [35–144] cells/mL, p = 0.06).
Table 4 shows factors analyzed for association with inpatient
mortality for all patients [n = 120] in univariate analysis. A higher
BMRC TBM disease grade (2 or 3 versus 1: AOR [95% CI] = 3.0
[1.08–8.40], p = 0.04) remained predictive of mortality in
multivariate analysis (logistic regression model p = 0.007,
R2 = 0.12). Table 5 shows factors analyzed for association with
inpatient mortality for HIV-infected patients [n = 106] only. CD4+
count (for every 50 cells/mL drop in CD4+ count: AOR [95%
confidence interval [CI]] = 1.4 [1.03–1.96], p = 0.03) and a higher
BMRC TBM disease grade (2 or 3 versus 1: AOR [95% CI] =
4.8 [1.45–15.87], p = 0.01) remained predictive of mortality
Table 2. Laboratory and radiological investigation findings of patients with definite, probable and possible tuberculous meningitis
(TBM).
Definite TBM (n=47) Probable TBM (n=35) Possible TBM (n=38)
Blood results, median (IQR)
Hemoglobin (g/dL) 10.5 (9.1–13) 12 (10.7–13.2)* 10 (8–11.4)
White cell count (cells6109/L) 5.9 (4.3–8.5) 5.6 (4.5–7.7) 7.7 (5.4–10)
Sodium (mmol/L) 126 (123–130) 129 (127–133)** 130 (126–135)**
Cerebrospinal fluid results, median, (IQR)
Protein (g/L) 2.6 (1.6–4.8) 2.4 (1.3–5.2) 1.2 (0.8–1.9)**
Glucose (mmol/L) 1.6 (0.9–2.4) 1.9 (1.3–2.8) 2.7 (2.1–3.2)**
Lymphocytes (cells6106/L) 77 (23–199) 59 (23–143) 12 (0–31)**
Polymorphonuclear cells (cells6106/L) 7 (0–39) 12 (0–12) 0 (0–3)**
Features of TB elsewhere, n/N (%) 35/42 (83) 21/34 (62)* 31/38 (82)
Chest radiograph abnormalities 34/38 (89) 18/27 (67)* 24/38 (63)
Abdominal ultrasound abnormalities1 6/6 (100) 11/11 (100) 8/10 (80)
Extra-meningeal AFB on microscopy/M.tb cultured 9/47 (19) 5/35 (14) 12/38 (32)
CT brain abnormalities,
(excluding cerebral atrophy), n/N (%)1 11/16 (69) 21/23 (91)2 4/5 (80)3
Hydrocephalus 4/16 (25) 6/23 (26) 0/5 (0)
Meningeal enhancement 3/16 (19) 9/23 (39) 0/5 (0)
Infarct 5/16 (31) 12/23 (52) 1/5 (20)
IQR, interquartile range; n, number of patients; N, total number of patients for whom results were available; TB, tuberculosis; AFB, acid-fast bacilli; M.tb, Mycobacterium
tuberculosis; CT, computed tomography.
*Significantly different (p,0.05) from patients with definite TBM,
**p,0.01.
1N includes total number of patients who underwent procedure.
2Significantly more patients with probable TBM had CT brain performed compared to patients with definite TBM, p = 0.007.
3Significantly less patients with possible TBM had CT brain performed compared to patients with definite TBM, p = 0.04.
doi:10.1371/journal.pone.0020077.t002
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Figure 2. Kaplan-Meier survival curves of patients with definite, probable and possible tuberculous meningitis (TBM). Survival
probability at 6-months was similar between patients with definite TBM and those with probable TBM (log-rank test p = 0.69), and possible TBM (log-
rank test p = 0.15).
doi:10.1371/journal.pone.0020077.g002
Table 3. Management and outcome of patients with definite, probable and possible tuberculous meningitis (n = 120).
TB treatment
On treatment at time of presentation, n/N (%) 26/115 (23)
Treatment started, n/N (%)1 84/89 (94)
Duration between symptom onset and starting treatment in days, median (IQR) 7 (3–13)
Corticosteroids started, n/N (%) ** 64/113 (57)
ART
Treatment started #6 months after starting TB treatment, n/N (%)2 31/54 (57)
Duration between diagnostic LP and starting ART in days, median (IQR) 42 (17–81)
Outcome3
Inpatient mortality, n (%) 45 (38)
Duration from LP to death in days4, median (IQR) 4 (3–9)
Six months, n (%)
Alive 50 (42)
Dead 58 (48)
Lost to follow-up 12 (10)
Nine months, n (%)
Alive 47 (39)
Dead 59 (49)
Lost to follow-up 14 (12)
TB, tuberculosis; n, number of patients; N, number of patients for whom results were available; IQR, interquartile range; LP, lumbar puncture; ART, antiretroviral therapy;
TBM, tuberculous meningitis; D4T, stavudine 30 mg twice daily; 3TC, lamivudine 150 mg twice daily or 300 mg daily; EFV, efavirenz 600 mg nightly; AZT, zidovudine
300 mg twice daily; tenofovir 300 mg daily.
**Significantly more patients with definite TBM (71%) received corticosteroid treatment compared to patients with possible TBM (32%, p,0.01).
1N includes patients not on TB treatment at presentation.
2N includes HIV-infected patients not on ART at presentation who survived admission. Treatment regimens included: 1) D4T, 3TC, EFV (n = 14) 2) AZT, 3TC, EFV (n = 7) 3)
3TC, TDF, EFV (n = 3). Treatment regimes were not known for 7 patients.
3Outcomes reported for all patients (n = 120) with TBM.
4Only including patients who died during hospitalization.
doi:10.1371/journal.pone.0020077.t003
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Table 4. Univariate analysis of variables associated with inpatient mortality in all patients with definite, probable and possible
tuberculous meningitis (n = 120).
Died (n=45) Survived (n =75) P-value OR1 (95% CI)
Age, median years (IQR) (N = 120) 37 (28–41) 35 (28–44) 0.97 - -
Female, n (%) (N = 120) 24 (55) 36 (48) 0.71 1.2 (0.59–2.60)
History of previous TB, n (%) (N = 115) 13 (30) 21 (29) 1.00 1.1 (0.46–2.40)
On TB treatment at time of LP, n (%) (N = 115) 9 (21) 18 (25) 0.66 0.79 (0.32–1.97)
HIV-infected, N (%) (N = 114) 39 (98) 67 (91) 0.26 4.1 (0.48–34.38)
BMRC TBM disease grade 2 or 3, n (%)(N = 114) 36 (84) 45 (63) 0.03* 3.0 (1.16–7.63)
Definite TBM, n (%) (N = 120) 18 (40) 29 (39) 1.00 1.1 (0.50–2.25)
WCC, median cells6109/L (IQR) 6.2 (4.5–8.9) 6.0 (4.6–9) 0.83 - -
Hemoglobin, median g/dL (IQR) 10.3 (8.8–12.3) 11 (9.6–12.8) 0.16 - -
Serum sodium, median mmol/L (IQR) 127 (124–133) 129 (125–134) 0.48 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–14) 0 (0–14) 0.61 - -
CSF lymphocytes, median cells6106 (IQR) 39 (8–144) 46 (16–125) 0.78 - -
CSF protein, median g/L (IQR) 2.28 (1.51–4.87) 1.76 (1.05–3.08) 0.11 - -
CSF glucose, median mmol/L (IQR) 1.8 (1–2.8) 2.2 (1.5–2.9) 0.19 - -
Symptoms to TB treatment, median days (IQR) 7 (2–12) 6 (4–14) 0.37 - -
Corticosteroids started, n (%)(N = 113) 21 (50) 43 (61) 0.33 0.7 (0.30–1.41)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; BMRC, British
Medical Research Council; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
p-value statistically significant (,0.05).
1Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t004
Table 5. Univariate analysis of variables associated with inpatient mortality in HIV-infected patients with definite, probable and
possible tuberculous meningitis (n = 106).
Died (n =39) Survived (n=67) P-value OR1 (95% CI)
Age, median years (IQR) (N = 106) 37 (28–41) 34 (28–44) 0.88 - -
Female, n (%) (N = 106) 19 (49) 38 (57) 0.54 0.7 (0.33–1.60)
History of previous TB, n (%) (N = 102) 13 (35) 19 (29) 0.66 1.3 (0.55–3.10)
On TB treatment at time of LP, n (%)(N = 101) 9 (24) 17 (27) 1.00 0.88 (0.35–2.26)
On ART at time of LP, n (% of HIV-infected) (N = 103) 8 (22) 12 (18) 0.80 1.2 (0.46–3.38)
CD4 at presentation, median cells/mL (IQR) 54 (23–143) 109 (40–170) 0.03* - -
BMRC TBM disease grade 2 or 3, n (%) (N = 100) 30 (81) 39 (62) 0.07 2.64 (1.002–6.94)
Definite TBM, n (%) (N = 106) 16 (41) 27 (40) 1.00 1.03 (0.46–2.30)
WCC, median cells6109/L (IQR) 6.2 (4.4–8.9) 5.6 (4.4–8.9) 0.60 - -
Hemoglobin, median g/dL (IQR) 9.9 (8.5–11.5) 10.9 (9.4–12.6) 0.09 - -
Serum sodium, median mmol/L (IQR) 127 (124–134) 129 (125–134) 0.96 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–16) 0 (0–12) 0.92 - -
CSF lymphocytes, median cells6106 (IQR) 42 (7–135) 46 (10–130) 0.80 - -
CSF protein, median g/L (IQR) 2.01 (1.26–3.00) 1.72 (1.04–3.09) 0.48 - -
CSF glucose, median mmol/L (IQR) 1.93 (0.9–2.8) 2.2 (1.6–2.9) 0.22 - -
Symptoms to TB treatment, median days (IQR) 7 (2–14) 6 (4–14) 0.40 - -
Corticosteroids started, n (%)(N = 99) 19 (53) 36 (57) 0.68 0.84 (0.36–1.91)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; ART, antiretroviral
therapy; BMRC, British Medical Research Council; CD4, CD4+ cell count; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
*p-value statistically significant (,0.05).
1Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t005
Tuberculous Meningitis in a HIV Prevalent Setting
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20077
in multivariate analysis (logistic regression model p = 0.01, R2 =
0.14).
Analysis of factors associated with six-month mortality is
reported only for HIV-infected hospital survivors for whom
outcome was known at six-months follow-up (n = 56, Table 6).
Being either on ART at presentation, or having started ART
during TB treatment, was negatively associated with six-month
mortality (OR = 0.2, 95% CI = 0.05–0.81, p = 0.03). This associ-
ation was confirmed in a Cox proportional hazard model (n = 66),
which included 10 HIV-infected patients who were lost to follow-
up after discharge (Figure 3, hazard ratio = 0.30, 95% CI = 0.08–
0.82, p = 0.03). No additional factors were associated with six-
months mortality when all patients (regardless of HIV-status) with
a known outcome at six-month follow-up were included in analysis
(data not shown).
Discussion
Several studies have reported CM as the most frequent cause of
meningitis in HIV-infected patients [1–3,16,17]. In our study,
TBM was the most common cause of meningitis (57%) when both
microbiological-confirmed cases and cases diagnosed on clinical
grounds were included. An earlier study conducted at our hospital
(2006–2008) reported CM and TBM as the cause of microbio-
logical-confirmed meningitis in 63%, and 28% of cases, respec-
tively [3]. By comparison, we found TBM (44%) and CM (45%) to
account for similar proportions of microbiological-confirmed
cases. This change may reflect increasing ART access in the
referral area (during 2009, 23 449 patients were commenced on
ART in the Western Cape public health sector, compared to
19 527 patients during 2008 [Catherine White, Western Cape ART
Monitoring and Evaluation Programme- personal communication]) and
therefore fewer HIV-infected patients reaching the severity of
immunosuppression associated with CM.
A higher BMRC TBM disease grade was predictive of death
during hospitalization when all patients (regardless of HIV status)
were included in the analysis. When the analysis was restricted to
HIV-infected patients only, both a lower CD4+ and a higher
BMRC TBM disease grade were associated with death. The
predictive value of worse TBM disease on the mortality of both
HIV-infected [18,19] and uninfected [20,21] patients is well
documented. Two previous studies also found an association
between low CD4+ count (less than 50 cells/mL [18] and less than
200 cells/mL [22]) and inpatient mortality in HIV-infected TBM
patients. However, this finding has not always been reproduced
[19,23]. Other factors previously reported associated with reduced
hospital survival in HIV-associated TBM include disease duration
of more than 14 days [22] and infection with MDR-TB strains
[18]. In our study, prolonged symptom duration was not
associated with inpatient mortality. Due to the low prevalence of
MDR-TB (MDR-TB isolates identified in 3 patients; 1 from CSF
and 2 from extra-meningeal specimens), its influence on mortality
could not be assessed.
In this study, six-month mortality in HIV-infected TBM
patients was significantly lower in patients who received ART
during TB treatment. As most studies in HIV-infected TBM
patients thus far were conducted in patients not receiving ART
[24], few have assessed the influence of ART on outcome. Torok
et al. [10] reported lack of ART prior to or during TB treatment to
Table 6. Univariate analysis of variables associated with six-month mortality in HIV infected patients with definite, probable and
possible tuberculous meningitis (n = 56).1
Died (n =12) Survived (n =44) P-value OR2 (95% CI)
Age, median years (IQR) (N = 56) 36 (29–49) 34 (28–44) 0.58 - -
Female, n (%) (N = 56) 3 (25) 19 (43) 0.33 0.4 (0.10–1.85)
History of previous TB, n (%) (N = 55) 5 (42) 13 (30) 0.50 1.6 (0.44–6.17)
On TB treatment at time of LP, n (%) (N = 54) 4 (33) 11 (26) 0.72 1.4 (0.36–5.62)
On ART at time of LP, n (% of HIV-infected) (N = 56) 1 (8) 10 (23) 0.42 0.3 (0.35–2.70)
CD4 at presentation, median cells/mL (IQR) 98 (18–160) 104 (46–159) 0.46 - -
BMRC TBM disease grade 2 or 3, n (%)(N = 54) 6 (50) 26 (62) 0.52 0.6 (0.17–2.24)
Definite TBM, n (%) (N = 56) 3 (25) 20 (45) 0.32 0.4 (0.10–1.68)
WCC, median cells6109/L (IQR) 6.8 (4.8–9.4) 5.6 (4.1–9.4) 0.56 - -
Hemoglobin, median g/dL (IQR) 9.7 (8.4–12.2) 10.6 (8.9–12.2) 0.60 - -
Serum sodium, median mmol/L (IQR) 134 (126–135) 128 (123–131) 0.09 - -
CSF polymorphs, median cells6106 (IQR) 0 (0–22) 2 (0–12) 0.42 - -
CSF lymphocytes, median cells6106 (IQR) 17 (0–67) 79 (19–172) 0.06 - -
CSF protein, median g/L (IQR) 1.28 (0.80–2.42) 1.91 (1.08–4.09) 0.12 - -
CSF glucose, median mmol/L (IQR) 2.2 (1.5–2.9) 2.3 (1.7–3.2) 0.97 - -
Symptoms to TB treatment, median days (IQR) 8 (4–48) 7 (4–17) 0.74 - -
Corticosteroids started, n (%)(N = 54) 5 (42) 25 (60) 0.33 0.5 (0.13–1.79)
ART started prior to LP/during TB treatment, n (%) (N = 56) 5 (42) 34 (77) 0.03* 0.2 (0.05–0.81)
n, number of patients; N, total number of patients for whom analysis was performed; IQR, interquartile range; TB, tuberculosis; LP, lumbar puncture; ART, antiretroviral
therapy; BMRC, British Medical Research Council; CD4, CD4+ cell count; WCC, total blood white cell count ; CSF, cerebrospinal fluid.
*p-value statistically significant (,0.05).
1Analysis performed for HIV-infected patients who survived hospitalization for whom outcome was known at 6-month follow-up. One HIV-infected hospital survivor for
whom ART treatment at TBM presentation was unknown excluded from analysis.
2Odds ratios (OR) and 95% confidence intervals (95%CI) reported for categorical variables.
doi:10.1371/journal.pone.0020077.t006
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be associated with earlier time to death by univariate, but not
multivariate, analysis in adult TBM patients. However, a
subsequent randomised trial conducted at the same site found
no significant difference in nine-month mortality between HIV-
infected TBM patients who started ART before or at two months
of TB treatment (58% mortality), compared to the historical
comparator group most of whom were not exposed to ART (67%
mortality) [9,10]. Croda et al. [8] found a history of ART prior to
TBM presentation to be predictive of death at nine-months follow-
up. The authors postulate that this surprising finding most likely
related to non-compliance to ART.
Contrary to inpatient mortality rates which are generally similar
between HIV-infected and uninfected patients with TBM
[22,23,25,26], six to nine-month outcome is substantially worse in
HIV-infected patients [14,27–29]. HIV-related illnesses (other than
TBM) probably account for a substantial proportion of deaths after
hospital discharge in HIV-infected TBM patients, particularly those
not on ART. As previous studies in HIV-associated TB have shown
a clear survival benefit in patients receiving ART [6,7], it is intuitive
to infer a causal relationship between ART and improved survival
in our patient cohort. However, survival-bias might also have
contributed to the association of ART and reduced mortality at six-
month follow-up that we observed: those who survived were able to
initiate ART.
Our study has several important limitations, which may have
resulted in bias. Firstly, due to its retrospective nature, not all
information was available in all cases. Specifically, a substantial
proportion of chest radiographs (14%) were not available for
review. This might have resulted in an underestimate of patients
with probable TBM. The reasons for a substantial proportion of
HIV-infected patients (43% of ART naı¨ve patients who survived
admission) failing to start ART after discharge could not be
determined. Patients are not routinely followed-up at our facility
after discharge from hospital; eligible patients are referred to their
local ART clinics to start ART. Alternatively, patients who require
prolonged admission may commence ART during admission to a
step-down facility. Limited access to primary care clinic and step-
down facility clinical records precluded the systematic collection of
data regarding reasons for failing to start ART, drug toxicities and
interactions, as well as co-morbidities after starting TB treatment
and ART. Also, adherence to ART and the proportion of patients
receiving directly observed TB treatment could not be assessed,
and causes of death were not determined. Although similar to
studies of TB patients previously conducted in our setting [30,31],
the loss to follow-up rate (10%) was not insubstantial. No factors
predictive of loss to follow-up could be confirmed by analysis of
baseline characteristics of these patients compared to those
retained in care. However, a trend to a lower CD4+ count was
observed in the latter group. Secondly, as study entry relied on
CSF findings, patients with TBM who died prior to LP, and those
who had a contraindication to LP based on brain CT, were not
included in the analysis.
Thirdly, HIV itself often results in mild CSF abnormalities [32].
For this reason, we did not include patients with mildly abnormal
CSF if a specific cause of meningitis was not found. However, it is
well documented that a minority of patients with TBM may
present with mildly abnormal, or completely normal CSF,
especially in the context of HIV co-infection [8,22,23,33]. This
group of patients would have been excluded from our study if CSF
TB microscopy and culture were negative. Furthermore, the
decision to perform CSF TB microscopy and culture was not
uniform, being based on the attending clinician’ s discretion.
Significantly less patients with possible and probable TBM
compared to definite TBM had CSF M. tuberculosis culture
performed; this could have resulted in the misclassification of
some patients with definite TBM who might have had M.
tuberculosis cultured had culture been performed.
Fourthly, CSF findings and neurological signs, most notably
focal neurological deficits (21% definite TBM versus 5% possible
TBM [p,0.01]), differed significantly between patients with
definite and possible TBM. This might reflect the inclusion of
some patients with alternative diagnoses such as viral meningitis as
possible TBM or, alternatively, be indicative of more severe
disease in patients with definite TBM. Patients with possible TBM
were also less likely, whilst those with probable TBM were more
likely, to undergo brain CT compared to patients with definite
Figure 3. Cox proportional hazard model survival curves. ART: HIV-infected tuberculous meningitis (TBM) patients either on antiretroviral
therapy (ART) at TBM presentation or started on ART during subsequent 6 months of antituberculosis (TB) treatment (n = 43). No ART: HIV-infected
TBM patients not on ART at presentation nor started on ART during subsequent 6 months of TB treatment (n = 23). The model only included patients
who survived hospitalization (n = 66). Hazard ratio for patients on ART= 0.30 (95% confidence interval 0.08–0.82, p-value= 0.03).
doi:10.1371/journal.pone.0020077.g003
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TBM (p = 0.04 and p = 0.007, respectively). This reflects the
limited resources in our setting: brain imaging in the context of
meningitis is usually prioritized to patients with severe disease or in
whom an intracerebral space occupying lesion is suspected i.e.
those with focal neurological deficits, severe depressed level of
consciousness or seizures. Both the differences in CSF findings and
the differences in the proportions of patients who underwent brain
imaging between the definite and possible TBM groups could have
resulted in bias, resulting in different corticosteroid prescription
practices between the 2 groups (71% definite TBM compared to
32% possible TBM, [p = 0.0007]) and possibly differentially
influencing outcomes. In our setting, corticosteroids are prescribed
at the treating clinician’s discretion.
Conclusions
In our setting where most patients with TBM are HIV co-
infected, advanced HIV and worse stage of TBM disease are poor
prognostic factors. Starting ART prior to or during TB treatment
may be associated with lower mortality in TBM patients co-
infected with HIV.
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